Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-09-07 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 Half-Year Continuous Supervision Tracking Report" issued by the sponsor institution Huatai United Securities Co., Ltd. for Jiangsu Haoubo Biopharmaceutical Co., Ltd. It covers the period January to June 2023 and includes detailed financial data, risk factors, business updates, use of raised funds, and governance information. The content is comprehensive and includes actual financial figures, operational and strategic analysis, risk disclosures, and compliance with regulatory requirements. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. The document is not a brief announcement or a certification letter, nor is it a full annual report. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-09-07 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于第三届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding matters discussed at the third meeting of the third board of directors. It references compliance with company law and stock exchange listing rules, and provides an independent judgment on a business expansion proposal. The document is short (709 characters) and consists mainly of opinions and signatures without detailed financial data or comprehensive report content. It is not a full annual report, audit report, or financial statement. It is also not a regulatory filing or announcement of voting results. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent director opinions on board decisions.
2023-09-05 Chinese
江苏浩欧博生物医药股份有限公司关于开展新业务的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. about launching a new business involving the exclusive introduction and sales of a series of desensitization drugs (Oraltek) in China. It includes strategic cooperation agreements, investment plans, regulatory approvals, risk disclosures, and business rationale. The document is not a financial report, earnings release, or management discussion but rather a corporate announcement about a new business initiative. It does not contain financial statements or quarterly/yearly results. It is not a regulatory filing or a report publication announcement since it is substantive and detailed. The content fits best under Capital/Financing Update (CAP) as it discusses new business investment, strategic cooperation, and capital deployment for new operations.
2023-09-05 Chinese
江苏浩欧博生物医药股份有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 half-year performance explanation meeting (业绩说明会) by Jiangsu Hob Biotech Co., Ltd. It provides the date, time, location, and participation instructions for the meeting, which is an investor presentation event. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the upcoming event where such information will be discussed. Therefore, it is classified as an Investor Presentation (IP). The document length is short (1525 characters), but it is not merely announcing the publication of a report; it is announcing the meeting itself, which fits the Investor Presentation category.
2023-09-04 Chinese
江苏浩欧博生物医药股份有限公司关于募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the delay of a fundraising investment project. It details the background of the fundraising, the original and adjusted timelines for project completion, reasons for the delay, and the impact on the company. It includes opinions from the board, independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but is focused on the update about the fundraising project timeline. It is not a full annual or interim report, nor an earnings release or audit report. It is a specific update related to capital use and fundraising projects. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is a substantive announcement, not merely a report publication notice or certification. Hence, the classification is CAP with high confidence.
2023-08-24 Chinese
江苏浩欧博生物医药股份有限公司关于2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) regarding the 2023 half-year fundraising funds deposit and actual usage situation of Jiangsu Haobo Biomedical Co., Ltd. It details the amount of funds raised, their deposit, usage, management, and investment projects status as of June 30, 2023. The document references regulatory guidelines on fundraising management and includes detailed tables on funds usage, investment projects, and cash management of idle funds. It is a comprehensive report focused on the management and use of capital raised through fundraising activities, specifically for the half-year period of 2023. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is longer than 5,000 characters and contains substantive financial data related to fundraising usage, not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2023-08-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.